Skip to content

Research at St Andrews

The implications of model–informed drug discovery and development for tuberculosis

Research output: Contribution to journalArticle

Author(s)

Morris Muliaditan, Geraint R. Davies, Ulrika S. H. Simonsson, Stephen H. Gillespie, Oscar Della Pasqua

School/Research organisations

Abstract

Despite promising advances in the field and highly effective first-line treatment, an estimated 9.6 million people are still infected with tuberculosis (TB). Innovative methods are required to effectively transition the growing number of compounds into novel combination regimens. However, progression of compounds into patients occurs despite the lack of clear understanding of the pharmacokinetic-pharmacodynamic (PK/PD) relations. The PreDiCT-TB consortium was established in response to the existing gaps in TB drug development. The aim of the consortium is to develop new preclinical tools in concert with an in silico model-based approach, grounded in PKPD principles. Here, we highlight the potential impact of such an integrated framework on various stages in TB drug development and on the dose rationale for drug combinations.
Close

Details

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalDrug Discovery Today
Volume22
Issue number3
Early online date28 Sep 2016
DOIs
StatePublished - Mar 2017

    Research areas

  • PKPD, Tuberculosis, Drug development , Modelling and simulation

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

    Kennedy, J. A., Baron, V. O., Hammond, R. J. H., Sloan, D. J. & Gillespie, S. H. 1 Aug 2018 In : Tuberculosis.

    Research output: Contribution to journalArticle

  2. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

  3. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: in the Cornell mouse model

    Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R. & Hu, Y. Jul 2018 In : Antimicrobial Agents and Chemotherapy. 62, 7, 9 p., e00190-18

    Research output: Contribution to journalArticle

  4. Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin

    Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. M. & Simonsson, U. S. H. 19 Jun 2018 In : Clinical Pharmacology & Therapeutics. Early View

    Research output: Contribution to journalArticle

Related by journal

  1. Recent progress in antiretrovirals - lessons from resistance

    Adamson, C. S. & Freed, E. O. May 2008 In : Drug Discovery Today. 13, 9-10, p. 424-432

    Research output: Contribution to journalArticle

ID: 246364035